newsfilter
← Latest News
PR Newswire·

New three-year real-world data on Leqembi® presented at CTAD 2026

  • BioArctic AB's partner Eisai presented new real-world results from the LEADER study at the 19th CTAD conference in Boston.
  • The analysis included 560 patients treated with Leqembi across 13 US clinical sites.
  • Patients treated with Leqembi showed a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia compared to a matched natural history cohort over 36 months.
  • Among 546 assessable patients after an average of 18 months, 81.1% remained stable or improved, with 75.8% stable and 5.3% improved.
  • 95.0% of all 560 patients were estimated to remain in early Alzheimer's disease stages through three years of treatment based on statistical modeling.
  • 87.5% of the 560 patients remained on Leqembi treatment at the time of chart extraction, with an average duration of 19 months.
  • Amyloid PET scans in 43 patients showed 77% became amyloid-negative at a median follow-up of 18.1 months.
  • Of patients reaching 18 months of treatment, 91.7% remained on Leqembi.
  • 218 patients transitioned to once-every-four-weeks intravenous (IV) maintenance, while 64 patients transitioned to once-weekly subcutaneous (SC) maintenance following its approval.
  • Among patients on monthly IV maintenance, 71.1% remained stable after an average of 26 months; among those on weekly SC maintenance, 76.6% remained stable after an average of 25.1 months.
  • All 64 patients receiving SC maintenance treatment remained on therapy at the time of chart extraction.
  • No ARIA events were reported during the SC maintenance period, with isolated ARIA-H reported in only 0.5% of patients during the IV maintenance period.
  • Clinical outcomes were consistent between sexes, with 79.3% of women and 83.3% of men reported as stable or improved.
  • Treatment persistence was similar across sexes, with 86.0% of females and 88.9% of males remaining on therapy at chart extraction.
  • ARIA incidence rates were generally consistent between female and male patients across all ARIA categories.
  • Overall safety findings in LEADER were consistent with the ALZ-NET registry and US prescribing information.
  • A separate international meta-analysis of approximately 5,000 patients showed a pooled total ARIA rate of 12.4%, compared to 21.5% in the Phase 3 Clarity AD study.
  • Symptomatic ARIA was reported in 0.8% of patients in the meta-analysis compared to 2.8% in Clarity AD.
  • Treatment discontinuation due to adverse events was 3.2% in the meta-analysis.
  • The study notes limitations inherent to retrospective real-world data, including potential biases and lack of placebo-controlled arms.
  • Leqembi is approved in 53 countries and is under regulatory review in six countries and regions as of November 2026.
  • BioArctic AB maintains a long-term collaboration with Eisai for the development and commercialization of lecanemab, with rights to commercialize in the Nordic region.
Company
BioArctic
Keywords
BioArctic